Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Dexcom (DXCM) over the last 16 years, with Q4 2025 value amounting to $106.2 million.

  • Dexcom's Change in Receivables rose 133513.51% to $106.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $201.9 million, marking a year-over-year increase of 47685.71%. This contributed to the annual value of $201.9 million for FY2025, which is 47685.71% up from last year.
  • As of Q4 2025, Dexcom's Change in Receivables stood at $106.2 million, which was up 133513.51% from -$237.8 million recorded in Q3 2025.
  • Over the past 5 years, Dexcom's Change in Receivables peaked at $187.2 million during Q4 2023, and registered a low of -$237.8 million during Q3 2025.
  • Over the past 5 years, Dexcom's median Change in Receivables value was $32.9 million (recorded in 2021), while the average stood at $38.6 million.
  • The largest annual percentage gain for Dexcom's Change in Receivables in the last 5 years was 246724.14% (2025), contrasted with its biggest fall of 52769.78% (2025).
  • Dexcom's Change in Receivables (Quarter) stood at -$15.1 million in 2021, then surged by 1082.12% to $148.3 million in 2022, then grew by 26.23% to $187.2 million in 2023, then tumbled by 96.05% to $7.4 million in 2024, then soared by 1335.14% to $106.2 million in 2025.
  • Its last three reported values are $106.2 million in Q4 2025, -$237.8 million for Q3 2025, and $184.6 million during Q2 2025.